Premium
Brincidofovir clearance of acyclovir‐resistant herpes simplex virus‐1 and adenovirus infection after stem cell transplantation
Author(s) -
Voigt S.,
Hofmann J.,
Edelmann A.,
Sauerbrei A.,
Kühl J.S.
Publication year - 2016
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12582
Subject(s) - medicine , cidofovir , herpes simplex virus , mucositis , virology , hematopoietic stem cell transplantation , viral load , stem cell , meningoencephalitis , adenovirus infection , transplantation , simplexvirus , immunology , virus , aciclovir , herpesviridae , viral disease , chemotherapy , biology , genetics
Infections with adenovirus (AdV) and herpesviruses can result in considerable morbidity and mortality in pediatric hematopoietic stem cell transplant ( SCT ) recipients. Herpes simplex virus ( HSV ) reactivations are usually prevented by acyclovir ( ACV ) prophylaxis, whereas cidofovir ( CDV ) has been used off indication to manage AdV infections. We report a child with myelodysplastic syndrome undergoing multiple SCT , who experienced HSV ‐1 disease including severe mucositis and herpetic whitlow, as well as high viral load AdV DNA emia. Both ACV and CDV were ineffective; however, viral loads were decreased with brincidofovir, resulting in viral clearance. A subsequent Epstein–Barr virus disease with relevant meningoencephalitis responded to rituximab.